EVT Fundamental Analysis - EVOTEC SE

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to EVT. EVT was compared to 19 industry peers in the Life Sciences Tools & Services industry. While EVT seems to be doing ok healthwise, there are quite some concerns on its profitability. EVT does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

EVT had negative earnings in the past year.

In the past year EVT had a positive cash flow from operations.

The reported net income has been mixed in the past 5 years: EVT reported negative net income in multiple years.

Each year in the past 5 years EVT had a positive operating cash flow.

1.2 Ratios

With a Return On Assets value of -8.97%, EVT is not doing good in the industry: 89.47% of the companies in the same industry are doing better.

EVT has a Return On Equity of -19.87%. This is amonst the worse of the industry: EVT underperforms 89.47% of its industry peers.

		Industry Rank	Sector Rank
ROA	-8.97%
ROE	-19.87%
ROIC	N/A

ROA(3y)-7.25%

ROA(5y)-2.34%

ROE(3y)-14.29%

ROE(5y)-5.27%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

EVT has a worse Gross Margin (10.82%) than 89.47% of its industry peers.

EVT's Gross Margin has declined in the last couple of years.

EVT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	10.82%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-16.23%

GM growth 5Y-13.5%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EVT does not have a ROIC to compare to the WACC, probably because it is not profitable.

EVT has more shares outstanding than it did 1 year ago.

EVT has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, EVT has an improved debt to assets ratio.

2.2 Solvency

EVT has an Altman-Z score of 1.15. This is a bad value and indicates that EVT is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 1.15, EVT is doing worse than 68.42% of the companies in the same industry.

A Debt/Equity ratio of 0.48 indicates that EVT is not too dependend on debt financing.

EVT's Debt to Equity ratio of 0.48 is fine compared to the rest of the industry. EVT outperforms 68.42% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.48
Debt/FCF	N/A
Altman-Z	1.15

ROIC/WACCN/A

WACC7.33%

2.3 Liquidity

A Current Ratio of 2.12 indicates that EVT has no problem at all paying its short term obligations.

With an excellent Current ratio value of 2.12, EVT belongs to the best of the industry, outperforming 94.74% of the companies in the same industry.

EVT has a Quick Ratio of 2.03. This indicates that EVT is financially healthy and has no problem in meeting its short term obligations.

EVT has a Quick ratio of 2.03. This is amongst the best in the industry. EVT outperforms 94.74% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.12
Quick Ratio	2.03

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EVT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -136.17%.

The Revenue has decreased by -2.67% in the past year.

The Revenue has been growing by 12.29% on average over the past years. This is quite good.

EPS 1Y (TTM)-136.17%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-9.09%

Revenue 1Y (TTM)-2.67%

Revenue growth 3Y8.85%

Revenue growth 5Y12.29%

Sales Q2Q%-11.36%

3.2 Future

Based on estimates for the next years, EVT will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.75% on average per year.

The Revenue is expected to grow by 6.85% on average over the next years.

EPS Next Y59.73%

EPS Next 2Y35.6%

EPS Next 3Y28%

EPS Next 5Y19.75%

Revenue Next Year-2.27%

Revenue Next 2Y4.05%

Revenue Next 3Y6.5%

Revenue Next 5Y6.85%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVT. In the last year negative earnings were reported.

Also next year EVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EVT is valued more expensive than 89.47% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	1189.72

4.3 Compensation for Growth

A more expensive valuation may be justified as EVT's earnings are expected to grow with 28.00% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y35.6%

EPS Next 3Y28%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

EVT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

EVOTEC SE

FRA:EVT (11/27/2025, 7:00:00 PM)

5.814

+0.11 (+1.93%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)11-05 2025-11-05/bmo

Earnings (Next)N/A N/A

Inst Owners60.42%

Inst Owner ChangeN/A

Ins OwnersN/A

Ins Owner ChangeN/A

Market Cap2.06B

Revenue(TTM)756.33M

Net Income(TTM)-158.98M

Analysts78.46

Price Target9.23 (58.75%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-64.24%

Min EPS beat(2)-106.63%

Max EPS beat(2)-21.86%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-6.97%

Min Revenue beat(2)-9.17%

Max Revenue beat(2)-4.77%

Revenue beat(4)0

Avg Revenue beat(4)-4.99%

Min Revenue beat(4)-9.17%

Max Revenue beat(4)-0.93%

Revenue beat(8)1

Avg Revenue beat(8)-3.74%

Revenue beat(12)4

Avg Revenue beat(12)1.12%

Revenue beat(16)7

Avg Revenue beat(16)2.95%

PT rev (1m)-2.29%

PT rev (3m)-3.03%

EPS NQ rev (1m)733.33%

EPS NQ rev (3m)733.33%

EPS NY rev (1m)5.49%

EPS NY rev (3m)5.08%

Revenue NQ rev (1m)4.39%

Revenue NQ rev (3m)6.28%

Revenue NY rev (1m)0%

Revenue NY rev (3m)-1.11%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	2.73
P/FCF	N/A
P/OCF	1464.25
P/B	2.58
P/tB	4.13
EV/EBITDA	1189.72

EPS(TTM)-1.11

EYN/A

EPS(NY)-0.18

Fwd EYN/A

FCF(TTM)-0.26

FCFYN/A

OCF(TTM)0

OCFY0.07%

SpS2.13

BVpS2.25

TBVpS1.41

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-8.97%
ROE	-19.87%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	10.82%
FCFM	N/A

ROA(3y)-7.25%

ROA(5y)-2.34%

ROE(3y)-14.29%

ROE(5y)-5.27%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-16.23%

GM growth 5Y-13.5%

F-Score4

Asset Turnover0.43

Health

		Industry Rank	Sector Rank
Debt/Equity	0.48
Debt/FCF	N/A
Debt/EBITDA	209.82
Cap/Depr	90.72%
Cap/Sales	12.19%
Interest Coverage	N/A
Cash Conversion	76.3%
Profit Quality	N/A
Current Ratio	2.12
Quick Ratio	2.03
Altman-Z	1.15

F-Score4

WACC7.33%

ROIC/WACCN/A

Cap/Depr(3y)186.39%

Cap/Depr(5y)182.37%

Cap/Sales(3y)22.79%

Cap/Sales(5y)21.48%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-136.17%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-9.09%

EPS Next Y59.73%

EPS Next 2Y35.6%

EPS Next 3Y28%

EPS Next 5Y19.75%

Revenue 1Y (TTM)-2.67%

Revenue growth 3Y8.85%

Revenue growth 5Y12.29%

Sales Q2Q%-11.36%

Revenue Next Year-2.27%

Revenue Next 2Y4.05%

Revenue Next 3Y6.5%

Revenue Next 5Y6.85%

EBIT growth 1Y-6.57%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year132.47%

EBIT Next 3Y50.57%

EBIT Next 5Y33.86%

FCF growth 1Y52.83%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y107.69%

OCF growth 3Y-46.98%

OCF growth 5Y-15.47%

EVOTEC SE / EVT.DE FAQ

Can you provide the ChartMill fundamental rating for EVOTEC SE?

ChartMill assigns a fundamental rating of 3 / 10 to EVT.DE.

Can you provide the valuation status for EVOTEC SE?

ChartMill assigns a valuation rating of 1 / 10 to EVOTEC SE (EVT.DE). This can be considered as Overvalued.

How profitable is EVOTEC SE (EVT.DE) stock?

EVOTEC SE (EVT.DE) has a profitability rating of 1 / 10.

How financially healthy is EVOTEC SE?

The financial health rating of EVOTEC SE (EVT.DE) is 5 / 10.

EVOTEC SE (EVT.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

EVOTEC SE / EVT.DE FAQ

Can you provide the ChartMill fundamental rating for EVOTEC SE?

Can you provide the valuation status for EVOTEC SE?

How profitable is EVOTEC SE (EVT.DE) stock?

How financially healthy is EVOTEC SE?